Top ▲
Target id: 2832
Nomenclature: egl-9 family hypoxia inducible factor 2
Abbreviated Name: PHD1
Family: Prolyl hydroxylases
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 407 | 19q13.2 | EGLN2 | egl-9 family hypoxia inducible factor 2 | |
Mouse | - | 419 | 7 15.83 cM | Egln2 | egl-9 family hypoxia-inducible factor 2 | |
Rat | - | 415 | 1q21 | Egln2 | egl-9 family hypoxia-inducible factor 2 | |
Gene and Protein Information Comments | ||||||
Using alternative methionine initiation codons, two isoforms of human EGLN2 have been reported , generating PHD1p40 (374 amino acids; UniProt identifier Q96KS0-2) and PHD1p43 (407 amino acids; UniProt identifier Q96KS0-1). PHD1p43 is considered the canonocal protein. |
Previous and Unofficial Names |
HIF prolyl hydroxylase 1 | HIFPH1 | egl-9 family hypoxia-inducible factor 2 |
Database Links | |
Alphafold | Q96KS0 (Hs), Q91YE2 (Mm), Q6AYU4 (Rn) |
BRENDA | 1.14.11.29 |
ChEMBL Target | CHEMBL3028 (Hs) |
Ensembl Gene | ENSG00000269858 (Hs), ENSMUSG00000058709 (Mm), ENSRNOG00000020947 (Rn) |
Entrez Gene | 112398 (Hs), 112406 (Mm), 308457 (Rn) |
Human Protein Atlas | ENSG00000269858 (Hs) |
KEGG Enzyme | 1.14.11.29 |
KEGG Gene | hsa:112398 (Hs), mmu:112406 (Mm), rno:308457 (Rn) |
OMIM | 606424 (Hs) |
Pharos | Q96KS0 (Hs) |
RefSeq Nucleotide | NM_080732 (Hs), NM_053046 (Hs), NM_053208 (Mm), NM_001004083 (Rn) |
RefSeq Protein | NP_542770 (Hs), NP_444274 (Hs), NP_444438 (Mm), NP_001004083 (Rn) |
UniProtKB | Q96KS0 (Hs), Q91YE2 (Mm), Q6AYU4 (Rn) |
Wikipedia | EGLN2 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
1. Desai RC, Pandaya V, Patel PR. (2014) Novel quinolone derivatives. Patent number: WO2014102818A1. Assignee: Cadila Healthcare Limited. Priority date: 24/12/2012. Publication date: 03/07/2014.
2. Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR. (2018) Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J Med Chem, 61 (16): 6964-6982. [PMID:29712435]
3. Vachal P, Miao S, Pierce JM, Guiadeen D, Colandrea VJ, Wyvratt MJ, Salowe SP, Sonatore LM, Milligan JA, Hajdu R et al.. (2012) 1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia. J Med Chem, 55 (7): 2945-59. [PMID:22364528]
Prolyl hydroxylases: egl-9 family hypoxia inducible factor 2. Last modified on 05/12/2022. Accessed on 10/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2832.